Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."

TSX:MSL - Post Discussion

MERUS LABS INTERNATIONAL INC > Peter Imhof on BNN today
View:
Post by mcintma on Feb 23, 2015 4:35pm

Peter Imhof on BNN today

Loves the subsector. Rates Merus #3 in the specialty pharma space behind Concordia and Knight, says Merus is cheap. GLTA

https://www.bnn.ca/Shows/Market-Call.aspx
Comment by retiredcf on Feb 24, 2015 8:17am
Second stock in the clip (at the end of his discussion on Biosyent). GLTA https://www.bnn.ca/Video/player.aspx?vid=557015 2015-02-23 BUY Peter Imhof Likes the story but the valuation is a bit too high. It is not that liquid of a stock. Hard to buy in a fund, but okay for individual investors. Prefers MSL-T. / Be the first to comment  ...more  
Comment by lscfa on Feb 24, 2015 9:35am
He never said MSL valuation was too high. That was RX. He said MSL was cheap.
MERUS LABS INTERNATIONAL INC
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities